BACKGROUND: Stage and histologic type have a significant impact on the long term clinical course of breast carcinoma. Clinical course is governed by two components: likelihood of cure and medial tumor-related survival time among uncured patients. Estimates of these components can be derived only by using survival models that incorporate cured fraction as a specific parameter. METHODS: The prognostic value of stage and histologic type was determined for 163,808 patients with breast carcinoma using the log normal and log logit cure-based survival models. Follow-up ranged from 1 month to 19 years and was obtained from the SEER Program. RESULTS: In approximate terms, ductal carcinoma was diagnosed in 70% of the patients, with estimate cured fractions of 2/3 and 1/3 for local and regional disease, respectively. Estimates of medial survival times for uncured patients were 10 and 5 years. Findings were similar for patients with tumor of miscellaneous histologic types. For patients with medullary carcinoma were 82% and 50%, with median survival times of 6 and 4 years. For patients with mucinous, lobular, and ductolobular carcinomas, parametric analysis gave inconsistent estimates of cured fraction, but findings suggested unusually long tumor-related survival times. CONCLUSIONS: Cured-based parametric survival models offer valuable insight into the impact of stage and histology on the clinical course of breast cancer.
BACKGROUND: Stage and histologic type have a significant impact on the long term clinical course of breast carcinoma. Clinical course is governed by two components: likelihood of cure and medial tumor-related survival time among uncured patients. Estimates of these components can be derived only by using survival models that incorporate cured fraction as a specific parameter. METHODS: The prognostic value of stage and histologic type was determined for 163,808 patients with breast carcinoma using the log normal and log logit cure-based survival models. Follow-up ranged from 1 month to 19 years and was obtained from the SEER Program. RESULTS: In approximate terms, ductal carcinoma was diagnosed in 70% of the patients, with estimate cured fractions of 2/3 and 1/3 for local and regional disease, respectively. Estimates of medial survival times for uncured patients were 10 and 5 years. Findings were similar for patients with tumor of miscellaneous histologic types. For patients with medullary carcinoma were 82% and 50%, with median survival times of 6 and 4 years. For patients with mucinous, lobular, and ductolobular carcinomas, parametric analysis gave inconsistent estimates of cured fraction, but findings suggested unusually long tumor-related survival times. CONCLUSIONS: Cured-based parametric survival models offer valuable insight into the impact of stage and histology on the clinical course of breast cancer.
Authors: J Huober; S Gelber; A Goldhirsch; A S Coates; G Viale; C Öhlschlegel; K N Price; R D Gelber; M M Regan; B Thürlimann Journal: Ann Oncol Date: 2012-06-14 Impact factor: 32.976
Authors: J M Del Casar; S González-Reyes; L O González; J M González; S Junquera; M Bongera; M F García; A Andicoechea; C Serra; F J Vizoso Journal: J Cancer Res Clin Oncol Date: 2009-11-15 Impact factor: 4.553
Authors: Isabelle Soerjomataram; Marieke W J Louwman; Jacques G Ribot; Jan A Roukema; Jan Willem W Coebergh Journal: Breast Cancer Res Treat Date: 2007-03-22 Impact factor: 4.872
Authors: R Clèries; A Ameijide; M Buxó; J M Martínez; R Marcos-Gragera; M-L Vilardell; M Carulla; Y Yasui; M Vilardell; J A Espinàs; J M Borràs; J Galceran; À Izquierdo Journal: Clin Transl Oncol Date: 2018-03-06 Impact factor: 3.405